interested in hearing replies to this one too. Also it appears that Lilly's soon to be released weekly GLP-1 has an edge on GSKs product. Is pricing/ formulary status of GSKs GLP projected to be more favorable than Lillys to make up for what looks to be a gap in efficacy between the products?
Since InVentiv will be in contract with GSK, the CI agreement will extend to InVentiv. This means those reps cannot be compensated with territory-level sales goals. It doesn't mean they will necessarily have to work under 'Patient First' (tests, COTS, etc) but they will not have sales quotas. Who knows, it might just be a salary only position, but that's purely speculation on my part.